Evotec (OTCMKTS:EVTCY) is scheduled to announce its earnings results before the market opens on Wednesday, August 14th.
Evotec (OTCMKTS:EVTCY) last released its quarterly earnings data on Tuesday, May 14th. The company reported $0.20 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.18 by $0.02. The firm had revenue of $118.01 million for the quarter. Evotec had a net margin of 23.40% and a return on equity of 20.00%. On average, analysts expect Evotec to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
EVTCY opened at $52.90 on Wednesday. The company has a market capitalization of $4.21 billion, a price-to-earnings ratio of 40.08 and a beta of 1.12. The firm’s 50-day moving average is $56.61. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.33 and a current ratio of 1.36. Evotec has a fifty-two week low of $35.57 and a fifty-two week high of $59.50.
A number of equities research analysts recently weighed in on EVTCY shares. Deutsche Bank downgraded shares of Evotec from a “buy” rating to a “hold” rating in a research note on Wednesday, April 10th. Zacks Investment Research cut shares of Evotec from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd.
Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates in two segments, EVT Execute and EVT Innovate. The EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services.
Recommended Story: Debt-To-Equity Ratio
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.